Go To Main TNBC Website


  New Posts New Posts RSS Feed - Chemo Regimen With Anthracycline Better
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Chemo Regimen With Anthracycline Better

 Post Reply Post Reply
Author
susanb View Drop Down
Senior Member
Senior Member


Joined: Mar 02 2008
Location: United States
Status: Offline
Points: 108
Post Options Post Options   Thanks (0) Thanks(0)   Quote susanb Quote  Post ReplyReply Direct Link To This Post Topic: Chemo Regimen With Anthracycline Better
    Posted: Apr 14 2017 at 10:31am
Dx June 06 stage 1 at age 46, no nodes, clean margins, Ki-67 at 54, Bilateral Mastectomy, 4 rounds AC, complete hysterectomy Aug O7. Mother and Grandmother both died of breast cancer dx in their 30's.
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12578
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Apr 14 2017 at 10:56am
Thank you for posting!

"About half the women were followed for less than 3 years and the other half of the women were followed for more than 3 years. The researchers recorded how long the women lived without a recurrence of invasive breast cancer, called invasive disease-free survival.

During follow-up, more women treated with the TC regimen had a recurrence than women treated with TaxAC:

  • 179 women treated with TC had a recurrence
  • 121 women treated with TaxAC had a recurrence

This difference was statistically significant, which means that it was likely due to the difference in chemotherapy regimens and not just because of chance.

Overall, 4-year invasive disease-free survival rates were:

  • 90.7% for the TaxAC regimen
  • 88.2% for the TC regimen

The results strongly suggest that the anthracycline regimen is slightly better than the regimen without an anthracycline for women diagnosed with early-stage, HER2-negative breast cancer with a high risk of recurrence."

  • For women with triple-negative disease (hormone-receptor-negative and HER2-negative) with no cancer in the lymph nodes, the TaxAC regimen reduced recurrence risk by 2.5% more than the TC regimen.
  • For women with triple-negative disease with one to three positive nodes, the TaxAC regimen reduced recurrence risk by 10.9% more than the TC regimen.
  • For women with triple-negative disease with four or more positive nodes or women with triple-negative disease with one or more positive nodes, the TaxAC regimen reduced recurrence risk by about 11% more than the TC regimen.
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
gordon15 View Drop Down
Senior Member
Senior Member


Joined: Jun 22 2015
Location: San Diego CA
Status: Online
Points: 749
Post Options Post Options   Thanks (0) Thanks(0)   Quote gordon15 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 17 2017 at 4:40pm
From everything I have read, and it's a lot, the "A" Adriamycin (chemical name: doxorubicin) is instrumental in killing cancer cells, my wife can't have any more chemo that includes Adriamycin because it can cause heart muscle damage over a certain lifetime limit.
wife: IDC/Lobular Stage2B 2008 lumpectomy/TAC+rads
TNBC Stage 3A/w/metaplastic/squamous Nov2015 Carboplatin-Gemzar chemo/masectomy Taxolchemo+rads 4-16
PET scan stable 9-2016/ 1-2017
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 11.05
Copyright ©2001-2016 Web Wiz Ltd.